Navigation Links
Heart scientists discover protein that may be 1 cause of heart failure
Date:5/23/2011

Researchers at the Peter Munk Cardiac Centre discovered a protein switch which can trigger a cascade of events leading to heart failure, pointing to a new direction for drug development.

Our research suggests that PINK1 is an important switch that sets off a cascade of events affecting heart cell metabolism, says Dr. Phyllis Billia, principal author, clinician‑scientist and heart failure specialist at the Peter Munk Cardiac Centre. This could be one of the inciting events in the development of heart failure.

The findings, published today in Proceedings of the National Academy of Sciences, show that the absence of a certain protein, PINK1, causes heart cells to produce less energy. This lack of energy causes some heart cells to die, forcing the remaining cells to work harder to keep the heart going. In response to this stress, the heart muscle cells thicken, a condition known as hypertrophy.

Heart failure is the most common cause of hospitalization in North American adults, and over 50,000 are treated for advanced heart failure annually. Transplantation is the only long-term treatment for end-stage heart failure patients and the long wait times for a matching donor organ make it necessary to find other alternatives.

"Heart Failure remains a silent epidemic in North America, except for those who suffer from this devastating disease. Current therapies, while effective, only target the symptoms of heart failure," says Dr. Vivek Rao, co-author of the study and Surgical Director of the Heart Transplant Program at the Peter Munk Cardiac Centre. "The discovery of PINK-1's role in the development of heart failure may lead to novel treatment to prevent heart failure in those at risk. This discovery represents a novel and as yet, untapped mechanism to fight the battle against heart failure."

In the lab, researchers "knocked-out" or genetically removed the PINK1 gene in mice and studied their heart cells under the microscope. They found that although the hearts initially develop normally, they begin to fail after two months, suggesting that PINK1 isn't required for organ development; rather it is crucial for protecting against heart failure.

Until now, research into the PINK1 gene has focused on its links to early-onset Parkinson's disease and certain cancers including esophageal and endometrial. This is the first study to establish its connection to heart disease.

While more research is required to develop potential clinical treatments, this discovery represents a new way of thinking about the involvement of certain proteins in the progression of heart failure.

"We need to learn more about PINK1 and the other proteins it interacts with at the sub-cellular level," says Dr. Billia. "But if we've identified the inciting event that causes the chain of events leading to failure, research and drug development strategies should be focused in this new area of science."


'/>"/>

Contact: Nicole Bodnar
nicole.bodnar@uhn.on.ca
416-340-4636
University Health Network
Source:Eurekalert

Related medicine news :

1. Younger Docs More Likely to Prescribe Drugs for Heart Disease: Study
2. Blood Pressure Drug Helps Those With Mild Heart Failure
3. Sleep Disorder Linked to Heart Rhythm Problems
4. Breakthrough medical food reverses risk of heart disease and diabetes
5. Dietary inorganic nitrate may reduce heart dysfunction caused by powerful anti-cancer drug
6. Standard Heart Drugs Wont Ease Pulmonary Hypertension
7. Extremely obese children have higher prevalence of psoriasis, higher heart disease risk
8. Simple fitness test could predict long-term risk for heart attack, stroke in middle-aged people
9. Dairy consumption does not elevate heart-attack risk, study suggests
10. Politics May Trump Looks, Personality in Matters of the Heart
11. What Protects the Heart May Also Ward Off Kidney Stones
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2017)... CT (PRWEB) , ... May 29, 2017 , ... ... to announce a new training program for Recovery Coaches who are seeking opportunities ... emergency rooms, court systems, treatment centers, and others. Recovery Coaching and Professionalism© was ...
(Date:5/29/2017)... Pittsburgh, PA (PRWEB) , ... May 29, 2017 , ... ... seemingly simple question: How do doctors determine if someone is cured? The virus has ... the most expensive and time-consuming tests. , Scientists at the University of Pittsburgh’s Graduate ...
(Date:5/28/2017)... ... 2017 , ... Viewers likely know Rob Lowe from such 80s hits as ... his work on NBC’s The West Wing and Parks and Recreation. But recently, Lowe’s ... which puts the spotlight on important modern-day issues that face today’s society. One of ...
(Date:5/27/2017)... ... ... Most us are familiar with the sound of occasional popping joints that ... shows that certain people who experience consistent joint popping, grating and grinding are ... opportunity to treat patients before the problem becomes pronounced, potentially hedging off more severe ...
(Date:5/26/2017)... ... ... Amir Qureshi, MD is the first physician in Arkansas to implant Nuvecta’s Algovita® ... Algovita SCS System has been FDA approved as a treatment option for chronic intractable ... the most powerful SCS system and the only stretchable lead on the market. This ...
Breaking Medicine News(10 mins):
(Date:5/26/2017)... May 25, 2017  In response to the opioid ... Direct Relief is working with Pfizer to make up ... no cost to community health centers, free and charitable ... "Pfizer has a long-standing commitment to ... ensuring patient safety through educational activities," said Caroline ...
(Date:5/22/2017)... , May 22, 2017  Lilac Corp, the ... announces the launch of a new website ... results of a clinical study that showed surprising ... with Gene-Eden-VIR/Novirin in individuals suffering from HPV warts, ... that there are no other treatments that clear ...
(Date:5/18/2017)... N.J. , May 17, 2017  Bayer announced ... oncology portfolio will be presented at the 53 rd ... Oncology (ASCO), taking place June 2-6 in ... presented at ASCO span prostate, colorectal, liver and thyroid ... analysis from the Phase II CHRONOS-1 trial of copanlisib ...
Breaking Medicine Technology: